Advertisement

Search Results

Advertisement



Your search for ASCO matches 21192 pages

Showing 8951 - 9000


issues in oncology

Eighth Edition of the AJCC Staging Manual Offers a More Personalized Approach to Patient Classification

This year marks the 60th anniversary of the creation of the American Joint Committee on Cancer (AJCC), whose founding mission was to standardize the anatomic staging of cancer based on the size of a tumor and any spread to nearby tissue (T); the spread of the cancer to nearby lymph nodes (N); and...

survivorship

The Role of Primary Care Physicians in Pediatric Cancer Survivorship

The symptoms related to childhood cancers that first prompt parents to seek medical care may be as nonspecific as those of the flu or a number of other common ailments. Therefore, a suspicion of cancer sometimes emerges during a visit to the child’s primary care physician. Although primary care...

Institute of Cancer Research Annual Science and Medical Image Competition

Each year, investigators from the Institute of Cancer Research (ICR), London, and the Royal Marsden NHS Trust collaborate to showcase images from their research to highlight the often unseen beauty of science. Maxine Lam, PhD,  a postdoctoral training fellow at ICR captured an image of a cancer...

breast cancer

Circulating Tumor DNA Analysis for Detection of Residual Disease in Breast Cancer

Researchers have developed a new method for tracking residual disease in patients with breast cancer that could one day help doctors better tailor treatments and prevent unnecessary surgeries for some people with the disease. Findings were published by McDonald et al in Science Translational...

hematologic malignancies

First-Degree Familial Risk in Blood Cancer Development

New data suggest that people who have a parent, sibling, or child with blood cancer have a higher likelihood of being diagnosed with a hematologic malignancy themselves. A study by Sud et al published in Blood offers the first...

skin cancer

Can Genetic Counseling and Test Reporting in Patients Susceptible to Melanoma Development Change Behavior?

A new study published by Stump et al in Genetics in Medicine investigated whether genetic testing would motivate people at risk of developing melanoma to alter their behavior in order to reduce their risk. “We are trying to understand whether a genetic test result adds value over and above...

Medicaid Patients Need Clinical Trial Access, Coalition Tells Congress

On July 10, ASCO led a coalition in a day of action in support of the Covering Life-Saving Investigations Needed in Cancer and Other Life-Threatening Conditions Through Timely Use of Resources for Easy and Affordable Treatment from Medicaid for Enrollees in Need Today Act (CLINICAL TREATMENT Act,...

issues in oncology

Cancer in Adults Aged 85 and Older: Rates, Screening, and Survival

A new report published by DeSantis et al in CA: A Cancer Journal for Clinicians examined cancer statistics in adults 85 and older and found incidence and mortality trends are generally similar to those in people aged 65 to 84 years, but disease screening rates are unexpectedly high and survival is...

Share ASCO Answers Fact Sheets With Your Patients

ASCO Answers are the ideal take-home resource for your patients. Direct, easy to understand, and in a convenient single-page format, ASCO Answers fact sheets introduce patients and their caregivers to types of cancer and cancer-related topics, including treatments and side effects. Each fact sheet...

hepatobiliary cancer

Aspirin Use May Improve Liver Function After Embolization for Hepatocellular Carcinoma

According to research published by Boas et al in the American Journal of Roentgenology, aspirin therapy is associated with improved liver function test results and survival after transarterial embolization for hepatocellular carcinoma. Findings In a retrospective review of 304 patients, among the ...

issues in oncology

Call for Papers: Physician Wellness, Burnout, and Moral Distress in Oncology Practice Special Series

The Journal of Oncology Practice (JOP) is pleased to announce a call for papers on a thematic issue devoted to physician burnout and moral distress in the adult and pediatric oncology setting. This special series will address ethical, cultural, social, personal, psychological, and organizational...

Conquer Cancer Honors Oncology Professionals With Merit Awards at the 2019 ASCO Annual Meeting

Conquer Cancer®, the ASCO Foundation, is pleased to announce the recipients of its 2019 ASCO Annual Meeting Merit Awards. These distinguished awards support oncology trainees who were first authors on abstracts selected for presentation at the ASCO Annual Meeting. This year, Conquer Cancer...

hematologic malignancies

ASH Honors Richard Aster, MD, With the Wallace H. Coulter Award for Lifetime Achievement in Hematology

The American Society of Hematology (ASH) will recognize Richard Aster, MD, of the Medical College of Wisconsin and Versiti Blood Center of Wisconsin in Milwaukee with the 2019 Wallace H. Coulter Award for Lifetime Achievement in Hematology. Dr. Aster will be honored for his significant...

rituxan
dacogen
imbruvica
venclexta

Highlights in Geriatric Hematology From the ASH Annual Meeting & Exposition

GUEST EDITOR Geriatrics for the Oncologist is guest edited by Stuart M. Lichtman, MD, FACP, FASCO, and developed in collaboration with the International Society of Geriatric Oncology (SIOG). Dr. Lichtman is an Attending Physician at Memorial Sloan Kettering Cancer Center, Commack, New York, and...

Sylvester Comprehensive Cancer Center Earns NCI Designation

Sylvester Comprehensive Cancer Center, part of the University of Miami Leonard M. Miller School of Medicine, has been named a National Cancer Institute (NCI)-designated cancer center. The NCI designation recognizes Sylvester as among the top cancer centers in the United States. Sylvester joins a...

health-care policy
immunotherapy

CMS Finalizes Decision to Cover CAR T-Cell Therapy for Medicare Beneficiaries

On August 7, the Centers for Medicare & Medicaid Services (CMS) finalized the decision to cover U.S. Food and Drug Administration (FDA)-approved chimeric antigen receptor (CAR) T-cell therapy among recipients of Medicare benefits. FDA-approved CAR T-cell therapies are approved to...

NCI Boosts University of Hawai’i Cancer Center Support to $8.4M

The National Cancer Institute (NCI) has increased monetary support to the University of Hawai’i (UH) Cancer Center from $5.7 million to $8.4 million and has extended the term of the current NCI designation by an additional year, until July 2022. The funding supports the core research infrastructure ...

Hope Cancer Care of Nevada Joins the American Oncology Network

The American Oncology Network, LLC (AON) has announced that Hope Cancer Care of Nevada, a leading community oncology/hematology practice in Las Vegas, will join AON, effective July 1, 2019. The American Oncology Network is an alliance of physicians and veteran health-care leaders working to ensure...

Broad Institute Launches Cancer Diagnostics Center

The Broad Institute of MIT and Harvard recently announced a new $15 million commitment by Louis V. Gerstner, Jr, former Corporate Executive Officer and Chairman of the Board of IBM Corporation, and Current Chairman of the Board of Directors of the Broad Institute, to create the Gerstner Center for...

COTA Signs Research Collaboration Agreement With FDA

COTA, Inc, a precision medicine technology company, announced that it has signed a 2-year Research Collaboration Agreement with the U.S. Food and Drug Administration (FDA) Information Exchange and Data Transformation (INFORMED) Program, the Agency’s data science and technology incubator that...

Leading City of Hope Hematologists Appointed to New Positions

Larry Kwak, MD, PhD, has been appointed the Deputy Director of City of Hope’s Hematologic Malignancies and Stem Cell Transplantation Institute. Tanya Siddiqi, MD, Associate Clinical Professor in City of Hope’s Department of Hematology & Hematopoietic Cell Transplantation, has been appointed...

bladder cancer

Johns Hopkins Awarded $3.2 Million NIH Grant for Early-Stage Bladder Cancer Research

Researchers at the Johns Hopkins Kimmel Cancer Center, the Greenberg Bladder Cancer Institute, the Bloomberg-Kimmel Institute for Cancer Immunotherapy, the Brady Urological Institute, and the Center for Computational Genomics at Johns Hopkins have received a $3.2 million grant from the National...

AACR Announces 2019 Class of Fellows of the AACR Academy

The American Association for Cancer Research (AACR) recently announced its newly elected class of Fellows of the AACR Academy. The mission of the AACR Academy is to recognize and honor distinguished scientists whose scientific contributions have propelled innovation and progress against cancer. The ...

hematologic malignancies
lymphoma

Treatment Update on Selected Non-Hodgkin Lymphomas

As part of The ASCO Post’s coverage of the 2019 ASCO Annual Meeting, featured here are four abstracts from different clinical trials evaluating newer treatments for Waldenström’s macroglobulinemia and T-cell lymphomas. Waldenström’s Macroglobulinemia ABSTRACT 7509: Outcomes with bendamustine plus ...

prostate cancer
issues in oncology

Androgen-Deprivation Therapy May Increase Risk for QT Prolongation and Torsades de Pointes

In a study published by Salem et al in Circulation, researchers examined how several testosterone-blocking drugs commonly used in the treatment of prostate cancer affect the heart's QT interval. The longer a QT interval—typically measured by an electrocardiogram—the more at risk a ...

skin cancer

Is Vitamin A Intake Linked to Cutaneous Squamous Cell Carcinoma Risk?

People whose diets included high levels of vitamin A had a 17% reduction in risk for developing cutaneous squamous cell carcinoma, as compared to those who ate modest amounts of foods and supplements rich in vitamin A. These findings were published by Kim et al in JAMA Dermatology. Vitamin A is...

MASCC’s 2019 Distinguished Service Award Winner

Rachel Gibson, PhD, was named the recipient of MASCC’s 2019 Distinguished Service Award, MASCC’s highest honor. The award is made in recognition of meritorious achievement and outstanding contributions to the society. Dr. Gibson has just been appointed inaugural Professor and Director, Allied...

solid tumors
head and neck cancer

Global Coalition for Adaptive Research in Glioblastoma

The Global Coalition for Adaptive Research (GCAR) announced recently that the GBM AGILE clinical trial is opening its first clinical site, the Henry Ford Cancer Institute, and has begun enrolling patients. GBM AGILE is the world’s first global adaptive clinical trial platform for glioblastoma and...

lymphoma

FDA Requests Manufacturer Recall of Some Textured Breast Implants

On July 24, the U.S. Food and Drug Administration (FDA) requested that Allergan, the manufacturer of a specific type of textured breast implant, recall specific models of its textured implants from the U.S. market due to the risk of breast implant–associated anaplastic large cell lymphoma (ALCL)....

immunotherapy

Blue Distinction Center for Cellular Immunotherapy Status Granted to Huntsman Cancer Institute

Huntsman Cancer Institute (HCI) at the University of Utah is the first Regence provider designated as a national Blue Distinction Center for Cellular Immunotherapy. Chimeric antigen receptor (CAR) T-cell therapy (CAR–T)-designated hospitals must be certified by a Risk Evaluation and Mitigation...

hematologic malignancies

FDA Approves Rituximab Biosimilar

On July 24, the U.S. Food and Drug Administration (FDA) approved rituximab-pvvr -(Ruxience), a biosimilar to rituximab (Rituxan), for the treatment of adult patients with non-Hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and granulomatosis with polyangiitis and microscopic polyangi-itis....

symptom management
supportive care

Novel Therapeutics on the Horizon for Treating Chemotherapy-Induced Peripheral Neuropathy

Chemotherapy-induced peripheral neuropathy is a major clinical problem, and better therapies are needed for both its treatment and prevention. According to Charles Loprinzi, MD, a medical oncologist at the Mayo Clinic in Rochester, Minnesota, to devise better preventive and treatment approaches,...

breast cancer
kidney cancer
sarcoma
lymphoma
multiple myeloma

Notable Presentations at ASCO 2019 Included Studies in Sarcoma, Lymphoma, Myeloma, and Breast and Kidney Cancers

The 2019 ASCO Annual Meeting featured a wealth of presentations on important topics. In addition to our regular news coverage of the meeting, we present below some highlights of other studies that add to our knowledge base for treatment of various cancers. Olaratumab in Soft-Tissue Sarcoma...

symptom management
immunotherapy

What Causes Liver Injury During Treatment With Pembrolizumab?

Immunotherapy as a treatment for advanced solid cancers has rapidly evolved over the past decade—often yielding remarkable results. However, its use has also given way to new adverse effects, including drug-induced gastrointestinal and liver toxicities. “Checkpoint inhibitors are a...

issues in oncology

Gender Equity

Diversity, inclusion, and gender equality were prevalent themes for 2019 that ran throughout the ASCO Annual Meeting. From the first year that featured free onsite child care for attendees, to a session on “Establishing a Mutually Respectful Environment in the Workplace,” as well as a Plenary...

supportive care
palliative care
pain management

How an Innovative AI-Based Smartphone Application Is Addressing Patients’ Palliative Care Needs

GUEST EDITOR Addressing the evolving needs of cancer survivors at various stages of their illness and care, Palliative Care in Oncology is guest edited by Jamie H. Von Roenn, MD, FASCO. Dr. Von Roenn is ASCO’s Vice President of Education, Science, and Professional Development.   During the 2019...

mektovi
erbitux
braftovi

BEACON CRC: Encorafenib/Binimetinib/Cetuximab Improves Survival in BRAF V600E–Mutated Metastatic Colorectal Cancer

The three-drug combination of encorafenib (a BRAF inhibitor), binimetinib (a MEK inhibitor), and cetuximab (an EGFR inhibitor) significantly improved overall survival in patients with BRAF-mutated metastatic colorectal cancer, according to the results of the phase III BEACON CRC clinical trial....

breast cancer

AI May Improve Efficiency and Accuracy of Digital Breast Tomosynthesis

Artificial intelligence (AI) may improve the efficiency and accuracy of an advanced imaging technology used to screen for breast cancer, according to a study published by Conant et al in Radiology: Artificial Intelligence. Digital breast tomosynthesis is an advanced method for cancer...

gastroesophageal cancer

Can Lymph Node Response to Neoadjuvant Chemotherapy Predict Prognosis in Esophageal Cancer?

In a study published by Urakawa et al in Annals of Surgery, researchers found that the response of lymph nodes to neoadjuvant chemotherapy is more effective in predicting disease recurrence and patient survival in individuals with esophageal cancer than the response of primary tumors....

gynecologic cancers

Prognostic Biomarker for Progression of Moderate Cervical Dysplasia

In a study published by Louvanto et al in Clinical Infectious Diseases, researchers investigated the ability of a DNA methylation panel to determine between disease progression and regression among women of childbearing age with untreated cervical intraepithelial dysplasia. In the majority of...

solid tumors

FDA Approves Pexidartinib for Tenosynovial Giant Cell Tumor

On August 2, the U.S. Food and Drug Administration (FDA) granted approval to pexidartinib (Turalio) capsules for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) associated with severe morbidity or functional limitations and not responsive to improvement with...

immunotherapy

What Causes Liver Injury During Treatment With Pembrolizumab?

Immunotherapy as a treatment for advanced solid cancers has rapidly evolved over the past decade—often yielding remarkable results. However, its use has also given way to new adverse effects, including drug-induced gastrointestinal and liver toxicities. “Checkpoint inhibitors are a game changer...

solid tumors
skin cancer
immunotherapy

FDA Pipeline: Breakthrough Therapy for Melanoma, Investigational New Drug for Advanced Solid Tumors

This week, the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation to bempegaldesleukin in combination with nivolumab for advanced melanoma and cleared an investigational new drug application for a phase I trial of SB 11285 in advanced solid tumors. Breakthrough...

lymphoma

Can Treatment With Antibiotics Inhibit Malignant T Cells in Cutaneous T-Cell Lymphoma?

Many patients with cutaneous T-cell lymphoma contract Staphylococcus aureus infections in the skin. In a new study, researchers have shown that aggressive treatment with antibiotics for patients with these infections not only inhibits the staphylococcal bacteria—but also the cancer...

prostate cancer

Adjuvant Radiotherapy After Radical Prostatectomy vs Radical Prostatectomy Alone in Patients With Positive Margins or Extracapsular Extension

In patients with prostate cancer with surgical positive margins or extracapsular extension of their disease, the risk of disease recurrence postprostatectomy is higher than in cases where the cancer cells are confined within the prostate. The Finnish FinnProstataX study investigated...

issues in oncology
global cancer care

Global Burden of Pediatric and Adolescent Cancer in 2017

A recent analysis looked at the global burden of pediatric cancer through the lens of years of affected and lost life. This work shows a much greater burden of childhood cancer, placed largely in low- and middle-income countries, than previous estimates. The findings were published in The Lancet...

skin cancer
issues in oncology

Survey Finds Majority of Americans Are Unfamiliar With Cutaneous Squamous Cell Carcinoma

Nearly-three quarters of Americans are not familiar with cutaneous squamous cell carcinoma, the second most common type of cancer in the United States, according to a new survey conducted by The Harris Poll on behalf of The Skin Cancer Foundation. Cutaneous squamous cell carcinoma is more common...

gastroesophageal cancer
immunotherapy

FDA Approves Pembrolizumab for Some Patients With PD-L1–Positive Esophageal Cancer

On July 30, the U.S. Food and Drug Administration (FDA) approved the programmed cell death protein 1 inhibitor pembrolizumab (Keytruda) as monotherapy for the treatment of patients with recurrent locally advanced or metastatic squamous cell carcinoma of the esophagus whose tumors express programmed ...

prostate cancer

FDA Approves Darolutamide for Nonmetastatic Castration-Resistant Prostate Cancer

On July 30, the U.S. Food and Drug Administration (FDA) approved darolutamide (Nubeqa) for the treatment of nonmetastatic castration-resistant prostate cancer. Approval was based on the ARAMIS study, a multicenter, double-blind, placebo-controlled clinical trial of 1,509 patients with...

issues in oncology
global cancer care

WHO Releases Report on the Global Tobacco Epidemic

Many governments are making progress in the fight against tobacco, with 5 billion people today living in countries that have introduced smoking bans, warnings on packaging, and other effective tobacco control measures—four times more people than a decade ago. However, a new World Health...

Advertisement

Advertisement




Advertisement